Comparison of outcomes between surgery and chemoradiotherapy after endoscopic resection for pT1a-MM with lymphovascular invasion or pT1b esophageal squamous cell carcinoma: Japanese multicenter propensity score-matched study

医学 淋巴血管侵犯 外科肿瘤学 危险系数 内科学 放化疗 食管鳞状细胞癌 倾向得分匹配 肿瘤科 腹部外科 食管癌 回顾性队列研究 比例危险模型 外科 胃肠病学 癌症 置信区间 转移
作者
Yoshinobu Yamamoto,Ryu Ishihara,Hirofumi Kawakubo,M. Nishikawa,Sachiko Yamamoto,Tomohiro Kadota,Seiichiro Abe,Masao Yoshida,Tsutomu Tanaka,Hiroaki Nagano,Hiroyoshi Nakanishi,Tetsuya Yoshizaki,Kotaro Waki,Akiko Takahashi,Yoshiyasu Kitagawa,Ken‐ichi Mizuno,Kenro Kawada,Yoshiyasu Kono,Chikatoshi Katada,Takashi Hashimoto,Yasuaki Nagami,Toshiyuki Yoshio,Toshio Shimokawa,Keiji Nihei,Kazuo Koyanagi,Ken Kato,Tomonori Yano,Manabu Muto,Yuko Kitagawa
出处
期刊:Journal of Gastroenterology [Springer Science+Business Media]
标识
DOI:10.1007/s00535-024-02188-7
摘要

Abstract Background Lymphovascular invasion (LVI) or pT1b is noncurative after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), and therefore surgery or chemoradiotherapy (CRT) is recommended. However, there has been debate regarding which treatment has better outcomes and whether individual risks should be considered. Methods This was a multicenter, retrospective study conducted at 65 hospitals in Japan. The inclusion criteria were patients with ESCC who underwent ER between January 2006 and December 2015, with pT1a-muscularis mucosa (MM) with LVI or pT1b, with negative vertical margins, cN0M0, and who underwent surgery or CRT. A 1:1 propensity score-matched analysis was performed between two groups. The primary and secondary end points were overall survival (OS) and relapse-free survival (RFS). OS and RFS were also compared between two subgroups: low risk (pT1a-MM with LVI and pT1b without LVI) and high risk (pT1b with LVI) for metastatic recurrence. Results Among 472 patients, 160 patients were selected from each group. The OS and RFS did not differ between surgery and CRT groups (hazard ratio, 0.887; P = .635 and hazard ratio, 1.036; P = .876, respectively). Subgroup analysis showed that CRT had a better prognosis in the low-risk group, and conversely, surgery had a better prognosis in the high-risk group. But these were not significant. The high-risk CRT group had a significant worse prognosis than the low-risk CRT group. Conclusions In patients with noncurative ER for ESCC, surgery and CRT showed no difference in long-term outcomes. Indications for CRT in the high-risk group need further investigation because of poor prognosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanxiqianxia完成签到,获得积分10
1秒前
俟天晴完成签到 ,获得积分10
3秒前
八十八夜的茶摘完成签到,获得积分10
6秒前
zzzllove完成签到 ,获得积分10
8秒前
ChatGPT完成签到,获得积分10
9秒前
12秒前
w婷完成签到 ,获得积分10
12秒前
lingkai完成签到 ,获得积分10
14秒前
我请问呢发布了新的文献求助10
20秒前
娃娃菜妮完成签到 ,获得积分10
24秒前
wcy完成签到 ,获得积分10
28秒前
MM发布了新的文献求助30
29秒前
优娜完成签到 ,获得积分10
31秒前
CipherSage应助健壮念寒采纳,获得10
31秒前
38秒前
小二郎应助英俊智宸采纳,获得10
48秒前
斯文败类应助SuyingGuo采纳,获得10
48秒前
量子星尘发布了新的文献求助10
50秒前
花海完成签到 ,获得积分10
55秒前
56秒前
57秒前
MM发布了新的文献求助30
1分钟前
英俊智宸发布了新的文献求助10
1分钟前
1分钟前
sci完成签到 ,获得积分10
1分钟前
Strongly发布了新的文献求助10
1分钟前
科研通AI6应助科研通管家采纳,获得10
1分钟前
1分钟前
Aluhaer应助科研通管家采纳,获得150
1分钟前
wanci应助科研通管家采纳,获得10
1分钟前
清爽尔岚完成签到 ,获得积分10
1分钟前
二中所长发布了新的文献求助10
1分钟前
guo完成签到,获得积分10
1分钟前
朱婷完成签到 ,获得积分10
1分钟前
冬雪完成签到 ,获得积分10
1分钟前
qing完成签到 ,获得积分10
1分钟前
1分钟前
cmh完成签到 ,获得积分10
1分钟前
英俊智宸完成签到,获得积分10
1分钟前
韭菜盒子发布了新的文献求助10
1分钟前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5139327
求助须知:如何正确求助?哪些是违规求助? 4338303
关于积分的说明 13512484
捐赠科研通 4177497
什么是DOI,文献DOI怎么找? 2290823
邀请新用户注册赠送积分活动 1291325
关于科研通互助平台的介绍 1233611